IMMUNOTECH-B (Immunotech Biopharm Ltd) has released an updated Terms of Reference for its Remuneration Committee, effective 20 March 2026. The committee, originally constituted on 6 June 2020, now operates under an expanded and more explicit governance framework aimed at reinforcing transparency and accountability in compensation decisions.

The revised charter confirms that the committee must comprise a majority of independent non-executive directors, with the chair also drawn from this group. A minimum quorum of two members is required, and the committee will meet at least once a year, with seven-day notice for regular meetings. Members may participate in person or through electronic means.

Key responsibilities include: • Formulating and recommending remuneration policy and structure for directors and senior management. • Reviewing management remuneration proposals against Board-approved corporate objectives. • Approving compensation packages, incentive schemes and share-based awards in accordance with Chapter 17 of the Hong Kong Listing Rules. • Ensuring no director participates in determining his or her own pay and evaluating termination payments for fairness and contractual compliance. • Reporting to the Board on deliberations and maintaining access to independent professional advice at the Company’s expense.

Administrative enhancements cover detailed minute-keeping, circulation of meeting records to the full Board, and a formal self-assessment mechanism to evaluate the committee’s effectiveness.

By refining these guidelines, IMMUNOTECH-B strengthens its corporate governance architecture, providing shareholders greater clarity on how director and executive remuneration is determined and overseen.